US FDA approves Gilead's once─daily oral Truvada for reducing risk of acquiring HIV─1 in adolescents

Gilead Sciences, Inc. announced that the US Food and Drug Administration (FDA) has approved once─daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)──in combination with safer sex practices

More From BioPortfolio on "US FDA approves Gilead's once─daily oral Truvada for reducing risk of acquiring HIV─1 in adolescents"